Fruzaqla (Fruquintinib)
fruquintinib 5 mg capsule, 21 · ORAL · PBS code 15344N
STREAMLINEDWhat it costs
AU$6595 PBS-determined price per 21 units
Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.
- • First listed on the PBS: 2026-05-01.
- • Repeats: 5.
- • PBS program: GE.
Eligibility criteria for subsidised access
The following is the government's own wording from the PBS Schedule, shown unchanged.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Metastatic colorectal cancer
Initial PBS-subsidised treatment
Patient must have/had a WHO performance status of 1 or less, prior to initiation of treatment with this drug for this condition; AND
Patient must not have previously received PBS-subsidised treatment with this drug for this PBS indication; or
Patient must be each of: (i) currently receiving non-PBS-subsidised supply for this drug for this PBS indication, (ii) untreated with this drug at the time that non-PBS-subsidised supply was commenced, (iii) free of disease progression since commencing non-PBS-subsidised supply; AND
Patient must have been previously treated with or not considered a candidate for treatment with fluoropyrimidine, oxaliplatin, irinotecan-based chemotherapies, an anti-vascular endothelial growth factor (anti-VEGF) agent and an anti-epidermal growth factor receptor (anti-EGFR) agent for this condition; AND
The treatment must be the sole PBS-subsidised therapy for this condition.
The patient's WHO performance status must be documented in the patient's medical records at the time the treatment is initiated.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Metastatic colorectal cancer
Continuing treatment
The treatment must be the sole PBS-subsidised therapy for this condition; AND
Patient must have previously been treated with PBS-subsidised treatment with this drug for this condition; AND
Patient must not develop progressive disease whilst receiving PBS-subsidised treatment with this drug for this condition.
Sponsor: Takeda Pharmaceuticals Australia Pty. Ltd. ABN 71 095 610 870
Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.